Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Immunic Inc (IMUX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$7.32-7.81%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for IMUX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Raise up to $400M through private placement | A primary condition in Immunic Inc's published investment case. The stated target is raise $400 million by 2026-Q1. | Intact | capital raised falls significantly below $400 million by 2026-Q1 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not a proven earnings compounder. The long-term thesis is in a watch state: management is focused on trial milestones and new leadership, while recent financial performance remains weak and confidence in the overall evidence is low.
The evidence snapshot does not provide a valuation level or clear expectations already reflected in the market, so whether IMUX is cheap or expensive versus peers cannot be assessed. It reports low fragility, meaning no listed signals point to concentrated fragility, but that does not resolve the valuation gap.
Near term, continued losses and negative operating cash flow point to ongoing funding needs, while management is pursuing a private placement of up to $400 million. The main multi-year fundamental driver is vidofludimus calcium, with Phase 3 results expected by year-end 2026 and a Phase 3 program planned in progressive MS; execution and leadership progress are mixed. A guidance cut is a stated risk, and the next results merit attention given the elevated risk and weak recent performance.
The thesis hinges on clinical progress, including the expected late-2026 trial data, and on whether the company can fund development. A guidance cut would weaken the near-term setup, while continued strength among named Healthcare bellwethers could support sector momentum. Those sector signals are secondary to IMUX’s own clinical and funding execution over the multi-year view.
Over the next 1 to 3 years, IMUX remains a low-confidence, high-risk clinical story whose thesis depends on trial progress and sufficient funding, with weak recent financial performance and management execution still in focus. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| New leadership may improve strategy and execution. |
| Intact |
| further CEO or key leadership departures before end of 2026 |
Qualitative: CEO/Chair stable, no C-suite departures Board chair named May 2026; Director Nash resigned Sept 2026 (orderly). No CEO or key executive departures reported. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 2 supplied quarters. Management reported: “Mr. Lundgren will lead Immunic as the company advances vidofludimus calcium through late-stage clinical development, including the pivotal phase 3 ENSURE program in relapsing multiple sclerosis (RMS) and the planned phase 3 program in primary progressive multiple sclerosis (PPMS), while also preparing for potential new drug application (NDA) filing, regulatory approval and commercialization.” Delivery assessment Nov 4, 2026 |
Manage net loss per share to -$1.08 or better | The company targets a net loss per share of $1.08 in 2026. | Intact | net loss per share worsens beyond -1.08 USD in FY26 | Diluted EPS: $-0.80 per share FY2026-Q2; GAAP. Published target: net loss per share >= -1.08 USD in FY26. Target period ends 2026-12-31; this observation covers 2026-Q2. Aug 11, 2026-0.8 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.55 → $-2.37 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.55 | $12,500,000 | 7 / 6 |
| 2026-07-25 | $-3.56 | $11,111,110 | 8 / 9 |
| 2026-07-26 | $-3.56 | $11,111,110 | 8 / 9 |
| 2026-07-27 | $-3.56 | $11,111,110 | 8 / 9 |
| 2026-07-28 | $-3.56 | $11,111,110 | 8 / 9 |
| 2026-07-29 | $-3.56 | $11,111,110 | 8 / 9 |
| 2026-07-30 | $-3.56 | $11,111,110 | 8 / 9 |
| 2026-07-31 | $-3.63 | $10,000,000 | 9 / 10 |
| 2026-08-01 | $-3.63 | $12,500,000 | 8 / 7 |
| 2026-08-02 | $-3.63 | $10,000,000 | 9 / 10 |
| 2026-08-03 | $-3.63 | $10,000,000 | 9 / 10 |
| 2026-08-04 | $-3.63 | $10,000,000 | 9 / 10 |
| 2026-08-05 | $-3.63 | $12,500,000 | 8 / 7 |
| 2026-08-06 | $-3.63 | $10,000,000 | 9 / 10 |
| 2026-08-07 | $-3.63 | $12,500,000 | 8 / 7 |
| 2026-08-08 | $-3.63 | $12,500,000 | 8 / 7 |
| 2026-08-09 | $-3.63 | $10,000,000 | 9 / 10 |
| 2026-08-10 | $-3.63 | $12,500,000 | 8 / 7 |
| 2026-08-12 | $-3.63 | $12,500,000 | 8 / 7 |
| 2026-08-13 | $-3.63 | $12,500,000 | 8 / 7 |
| 2026-08-14 | $-3.63 | $12,500,000 | 8 / 7 |
| 2026-08-15 | $-3.63 | $12,500,000 | 8 / 7 |
| 2026-08-16 | $-3.63 | $12,500,000 | 8 / 7 |
| 2026-08-17 | $-3.63 | $12,500,000 | 8 / 7 |
| 2026-08-18 | $-3.63 | $12,500,000 | 8 / 7 |
| 2026-08-19 | $-3.63 | $12,500,000 | 8 / 7 |
| 2026-08-20 | $-2.52 | $11,111,111 | 9 / 7 |
| 2026-08-21 | $-2.52 | $11,111,111 | 9 / 7 |
| 2026-08-22 | $-2.39 | $12,500,000 | 9 / 7 |
| 2026-08-23 | $-2.39 | $12,500,000 | 9 / 7 |
| 2026-08-24 | $-2.39 | $12,500,000 | 9 / 7 |
| 2026-08-25 | $-2.39 | $12,500,000 | 9 / 7 |
| 2026-08-26 | $-2.39 | $12,500,000 | 9 / 7 |
| 2026-08-27 | $-2.39 | $12,500,000 | 9 / 7 |
| 2026-08-28 | $-2.39 | $12,500,000 | 9 / 7 |
| 2026-08-29 | $-2.39 | $12,500,000 | 9 / 7 |
| 2026-08-30 | $-2.39 | $12,500,000 | 9 / 7 |
| 2026-08-31 | $-2.39 | $12,500,000 | 9 / 7 |
| 2026-09-01 | $-2.39 | $12,500,000 | 9 / 7 |
| 2026-09-02 | $-2.39 | $12,500,000 | 9 / 7 |
| 2026-09-03 | $-2.44 | $12,500,000 | 9 / 7 |
| 2026-09-04 | $-2.44 | $12,500,000 | 9 / 7 |
| 2026-09-05 | $-2.44 | $12,500,000 | 9 / 7 |
| 2026-09-06 | $-2.44 | $12,500,000 | 9 / 7 |
| 2026-09-07 | $-2.44 | $12,500,000 | 9 / 7 |
| 2026-09-08 | $-2.44 | $12,500,000 | 9 / 7 |
| 2026-09-09 | $-2.44 | $12,500,000 | 9 / 7 |
| 2026-09-10 | $-2.44 | $12,500,000 | 9 / 7 |
| 2026-09-11 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-12 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-13 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-14 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-15 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-16 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-17 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-18 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-19 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-20 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-21 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-22 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-23 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-24 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-25 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-26 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-27 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-28 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-29 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-09-30 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-01 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-02 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-03 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-04 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-05 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-06 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-07 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-08 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-09 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-10 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-11 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-12 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-13 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-14 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-15 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-16 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-17 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-18 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-19 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-20 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-21 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-22 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-23 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-24 | $-2.43 | $12,500,000 | 9 / 7 |
| 2026-10-25 | $-2.37 | $12,500,000 | 9 / 7 |
| 2026-10-26 | $-2.37 | $12,500,000 | 9 / 7 |
| 2026-10-27 | $-2.37 | $12,500,000 | 9 / 7 |
| 2026-10-28 | $-2.37 | $12,500,000 | 10 / 7 |
| 2026-10-29 | $-2.37 | $12,500,000 | 10 / 7 |
| 2026-10-30 | $-2.37 | $12,500,000 | 10 / 7 |
| 2026-10-31 | $-2.37 | $12,500,000 | 10 / 7 |
| 2026-11-01 | $-2.37 | $12,500,000 | 10 / 7 |
| 2026-11-02 | $-2.37 | $12,500,000 | 10 / 7 |
| 2026-11-03 | $-2.37 | $12,500,000 | 10 / 7 |
| 2026-11-04 | $-2.37 | $12,500,000 | 10 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 13 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.